Related Experiment Video
Updated: Mar 10, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
Alessandro De Vita1, Giacomo Miserocchi2, Federica Recine3
1Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014 Meldola (FC), Italy. alessandro.devita@irst.emr.it.
Abstract:
Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established. The anticancer activity of eribulin on the patient-derived primary culture was assessed by MTT and tunel assays. Eribulin efficacy was compared to other drugs approved for the treatment of STS. Cell migration and morphology were examined after exposure to eribulin to better understand the drug mechanism of action. Finally, Western blot analysis of apoptosis and migration proteins was performed. The results showed that eribulin exerts its antiproliferative effect by the arrest of cell motility and induction of apoptosis. Our results highlighted the activity of eribulin in the treatment of ALT/DDLPS patients.
Insights
Eribulin mesylate effectively treats advanced liposarcoma by halting cell movement and triggering apoptosis. This study confirms its efficacy in well-differentiated/dedifferentiated liposarcoma, offering a new therapeutic option for soft tissue sarcoma patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Eribulin mesylate is a synthetic microtubule inhibitor with demonstrated antitumor activity.
- It is approved for metastatic liposarcoma (LPS) post-anthracycline treatment.
- Well-differentiated/dedifferentiated LPS (ALT/DDLPS) is a common adipocytic sarcoma subtype.
Purpose of the Study:
- Investigate eribulin's mechanism of action in ALT/DDLPS.
- Assess eribulin's anticancer activity in patient-derived cells.
- Compare eribulin's efficacy against other soft tissue sarcoma (STS) treatments.
Main Methods:
- Established a primary ALT/DDLPS cell culture from patient tissue.
- Assessed anticancer activity using MTT and TUNEL assays.
- Analyzed cell migration, morphology, and protein expression via Western blot.
Main Results:
- Eribulin mesylate demonstrated antiproliferative effects in ALT/DDLPS.
- The drug arrested cell motility and induced apoptosis.
- Eribulin showed efficacy comparable to other STS treatments.
Conclusions:
- Eribulin mesylate is an effective treatment for ALT/DDLPS.
- Its mechanism involves inhibiting cell migration and promoting apoptosis.
- This study supports eribulin's use in treating specific liposarcoma subtypes.
